Coronary artery disease · 2026
Optimizing duration of renin-angiotensin system inhibition after ST-elevation myocardial infarction with drug-eluting stent-percutaneous coronary intervention: Real-World Landmark Evidence from the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Choi Byoung Geol, Kim Hae Don, Rha Seung-Woon, Lee Seung Uk, Park Soohyung, Chesario Manda Satria, Susanti Melly, Choi Cheol Won, Choi Cheol Ung, Jeong Myung Ho, Oh Dong Joo
Аннотация
BACKGROUND: Renin-angiotensin system inhibitors (RASi), including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, improve outcomes after acute myocardial infarction. However, in the drug-eluting stent (DES) era with routine percutaneous coronary intervention (PCI), the duration and timing of benefit after ST-elevation myocardial infarction (STEMI) remain uncertain.
METHODS: Using the nationwide prospective Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry, we identified STEMI patients who underwent successful DES-PCI and survived to discharge ( n = 5017). RASi exposure was defined at discharge for analyses from 0 to 12 months and reassigned at a 12-month landmark for analyses from 12 to 36 months, reflecting real-world switching or discontinuation. The primary outcome was all-cause mortality. Confounding was addressed using 1 : 1 propensity-score matching (851 pairs) and Cox proportional hazards models.
RESULTS: At discharge, 4093 patients received RASi and 924 did not. At 12 months, all-cause mortality was lower with RASi in the overall cohort [2.1 vs. 4.5%, hazard ratio: 0.45, 95% confidence interval (CI): 0.31-0.66, P < 0.001] and matched cohort (3.0 vs. 4.9%, hazard ratio: 0.61, 95% CI: 0.37-1.00, P = 0.050), driven by fewer cardiac deaths. Over 36 months, RASi was associated with lower mortality overall and after matching. From 12 to 36 months, landmark analyses showed neutral associations. First-year left ventricular ejection fraction and blood pressure improved more with RASi (both P < 0.01).
CONCLUSION: In STEMI treated with DES-PCI, RASi at discharge offers a survival benefit concentrated within the first year. After 12 months, associations were neutral among event-free survivors, supporting early initiation and maintenance of RAS inhibition with individualized reassessment beyond 1 year.
METHODS: Using the nationwide prospective Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry, we identified STEMI patients who underwent successful DES-PCI and survived to discharge ( n = 5017). RASi exposure was defined at discharge for analyses from 0 to 12 months and reassigned at a 12-month landmark for analyses from 12 to 36 months, reflecting real-world switching or discontinuation. The primary outcome was all-cause mortality. Confounding was addressed using 1 : 1 propensity-score matching (851 pairs) and Cox proportional hazards models.
RESULTS: At discharge, 4093 patients received RASi and 924 did not. At 12 months, all-cause mortality was lower with RASi in the overall cohort [2.1 vs. 4.5%, hazard ratio: 0.45, 95% confidence interval (CI): 0.31-0.66, P < 0.001] and matched cohort (3.0 vs. 4.9%, hazard ratio: 0.61, 95% CI: 0.37-1.00, P = 0.050), driven by fewer cardiac deaths. Over 36 months, RASi was associated with lower mortality overall and after matching. From 12 to 36 months, landmark analyses showed neutral associations. First-year left ventricular ejection fraction and blood pressure improved more with RASi (both P < 0.01).
CONCLUSION: In STEMI treated with DES-PCI, RASi at discharge offers a survival benefit concentrated within the first year. After 12 months, associations were neutral among event-free survivors, supporting early initiation and maintenance of RAS inhibition with individualized reassessment beyond 1 year.
Предметные рубрики MeSH
HumansRegistriesDrug-Eluting StentsPercutaneous Coronary InterventionRepublic of KoreaAngiotensin-Converting Enzyme InhibitorsST Elevation Myocardial InfarctionFemaleRenin-Angiotensin SystemMaleAgedMiddle AgedTime FactorsAngiotensin Receptor AntagonistsTreatment OutcomeProspective StudiesRisk Factors